An excellent Newsweek cover story today brings the sad news that antidepressants depressingly don’t work. Which is sad, because – among other reasons – a lot of people use them. What’s even worse, however, is that they work less than placebos.
One of the most controversial proposed disorders for the upcoming revision of psychiatry’s billing bible of mental disorders, (the DSM-5) is Psychosis Risk Syndrome (PRS) a “mental disorder” that, if voted into DSM, would confirm the allegations that psychiatry is manufacturing a Brave New World for itself—heavily backed by Big Pharma—of drugging children before they develop a “mental illness.”
Now Sen. Charles Grassley (R-Iowa), ranking Republican on the Senate Finance Committee, is investigating financial ties between Lilly and WebMD Health Corp. because of a WebMD TV ad exhorting people to undergo a Lilly depression screening.
Who is Patrick McGorry and what does he promote? He’s a psychiatrist just named Australian of the Year for his work in “youth mental health reform.” What does that reform consist of? What he calls a “new form of climate change.” It sure is. He not only promotes youths being put on antipsychotics and antidepressants, cited by international drug regulatory agencies as causing hallucinations, hostility, personality change, life-threatening diabetes, strokes, suicide and death, McGorry goes a giant step further—drug them before they’ve even developed a “psychiatric” disorder. The Association for the Accreditation of Human Research Protection Programs (AHRPP) likens such concepts to “performing mastectomies on women who are at risk of—but do not have—breast cancer.”
The FDA plans to increase misdemeanor prosecutions of industry execs as it looks to refocus its Office of Criminal Investigations. The move comes in response to a new report from the General Accountability Office that the OCI suffers from lax oversight, despite increased in funding and staffing over the past decade. In fact, the FDA hasn’t reviewed most OCI offices in more than three years. The OCI investigates counterfeit drugs and other bad stuff, as well as misconduct by FDA employees.